OR WAIT null SECS
August 27, 2021
FDA granted orphan drug designation for imatinib in AER-901 for the treatment of patients with pulmonary arterial hypertension.
August 26, 2021
Signal Rx Pharmaceuticals, Crystec, and ADYA Consulting are collaborating on the development of an inhaled dry powder formulation of SF2523 to treat pulmonary fibrosis, lung cancer, and SARS-CoV-2 related illnesses.
August 03, 2021
Dosage form priorities are shifting to focus on user-friendliness, leading to greater engagement with outsourcing partners earlier in development timelines.
August 01, 2021
The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
July 03, 2021
Particle performance in a DPI can be optimized by fine-tuning the formulation and manufacturing process parameters.
July 01, 2021
Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.
June 22, 2021
Vectura has signed an agreement with Incannex Healthcare for the pre-clinical development of IHL-216A, an inhaled drug product for the treatment of traumatic brain injury.
May 07, 2021
Vectura and Inspira Pharmaceuticals have joined forces to develop a potential inhaled therapy for COVID-19.
March 10, 2021
The expansion plans to increase Vectura’s DPI dosage form development, specifically its unit dose and multi-dose inhalers, and integrated device design and manufacturing for customer programs.
December 08, 2020
A development agreement will study inhaled formulations of cannabinoid-based drug product for central nervous system diseases.